

Amendments to the Specification:

Please replace the first and second paragraphs of page 1, lines 5-9, of the specification with the replacement sections entitled “Cross-Reference to Related Applications” and “Field of the Invention” as indicated in the “Replacement Section” on page 3 of this paper.

Replacement Section

-- CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S.S.N. 10/060,734 filed on January 30, 2002, now allowed, which is a continuation of U.S.S.N. 09/370,046, filed on August 6, 1999, now U.S. Patent No. 6,548,699, which is a continuation of U.S.S.N. 09/079,213 filed on May 14, 1998, now U.S. Patent No. 6,147,250, which claims priority to U.S. provisional application serial no. 60/047,020 filed on May 14, 1997, the disclosures of which are incorporated herein by reference.--

--FIELD OF THE INVENTION

This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases. --